Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can the timing of maintenance brain stimulation keep depression away longer?

NCT ID NCT07727005

Disease control Sponsor: Technical University of Munich Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This trial tests whether the schedule of maintenance transcranial magnetic stimulation (rTMS) affects the risk of depression relapse. Adults who responded to an initial course of theta burst stimulation are randomly assigned to receive 20 maintenance sessions either clustered together or spread out over 20 weeks. Researchers track depressive symptoms and relapse over 24 weeks to see which schedule better preserves the treatment response.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
repetitive transcranial magnetic stimulation (rTMS) using intermittent theta burst stimulation
What this could lead to
If one schedule works better, it could offer a more effective way to keep depression from returning after successful brain stimulation treatment.
What could go wrong
This is a mid-sized trial comparing two maintenance schedules, not a new treatment. The results may not apply to everyone with depression, and some people may still relapse.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * Diagnosis of a depressive syndrome * Completion of an acute treatment course consisting of 20 sessions of theta burst stimulation (TBS) over 4 weeks * Response or remission following acute treatment. Response is defined as a ≥50% reduction in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score * Remission is defined as a MADRS total score ≤10. * Clinical eligibility for maintenance TBS * Provision of written informed consent Exclusion Criteria: * Non-response to acute TBS treatment * Contraindications to transcranial magnetic stimulation (TMS) or theta burst stimulation (TBS) * Active substance use disorder (substance use within the past 3 months) * Acute psychiatric or medical conditions that preclude study participation Additional exclusion criteria for the MRI component: \- Contraindications to MRI (e.g., non-MRI-compatible metallic implants or severe claustrophobia)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Depressive episodes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

depressive disorder major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Depressive episodes Depressive syndrome Major depressive disorder (MDD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • TUM Universitiy Hospital, Department for Psychiatry and Psychotherapy

    Munich, Bavaria, 81675, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.